Targeting metabotropic glutamate receptors to develop novel antipsychotics

Japanese Journal of Neuropsychopharmacology

Volumn 30, Issue 5-6, 2010, Pages 207-213

  Chaki, Shigeyuki ^a   Yoshida, Shigeru ^a   Okuyama, Shigeru ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Antipsychotic; mGlu2 3 receptor agonist; mGlu5 receptor potentiator; Schizophrenia

Indexed keywords

4 [2 AMINO 4 (METHYLTHIO)BUTYRYLAMINO] 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; DOPAMINE; GLUTAMIC ACID; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SEROTONIN 2A RECEPTOR;

CLINICAL TRIAL; DOPAMINE RELEASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HUMAN; NEGATIVE SYNDROME; NONHUMAN; POSITIVE SYNDROME; PREFRONTAL CORTEX; REVIEW; SCHIZOPHRENIA;

AMINO ACIDS; ANIMALS; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE MODELS, ANIMAL; DOPAMINE; DRUG DESIGN; GLUTAMIC ACID; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA;

EID: 78650347569     PISSN: 13402544     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Adams, B. W. and Moghaddam, B. (2001) Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex. Biol Psychiatry, 50: 750-757.
2. Akil, M., Pierri, J. N., Whitehead, R. E., Edgar, C. L., Mohila, C., Sampson, A. R. and Lewis, D. A. (1999) Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry, 156: 1580-1589.
3. Benneyworth, M. A., Xiang, Z., Smith, R. L., Garcia, E. E., Conn, P. J. and Sanders-Bush, E. (2007) A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol Pharmacol, 72: 477-484.
4. Bishop, J. R., Ellingrod, V. L., Moline, J. and Miller, D. (2005) Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophr Res, 77: 253-260.
5. Brozoski, T. J., Brown, R. M., Rosvold, H. E. and Goldman, P. S. (1979) Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science, 205: 929-932.
6. Calcagno, E., Carli, M., Baviera, M. and Invernizzi, R. W. (2009) Endogenous serotonin and serotonin2C receptors are involved in the ability of M100907 to suppress cortical glutamate release induced by NMDA receptor blockade. J Neurochem, 108: 521-532.
7. Cartmell, J., Monn, J. A. and Schoepp, D. D. (1999) The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther, 291: 161-170.
8. Cartmell, J., Perry, K. W., Salhoff, C. R., Monn, J. A. and Schoepp, D. D. (2001) Acute increases in monoamine release in the rat prefrontal cortex by the mGlu2/3 agonist LY379268 are similar in profile to risperidone, not locally mediated, and can be elicited in the presence of uptake blockade. Neuropharmacology, 40: 847-855.
9. Conn, P. J., Lindsley, C. W. and Jones, C. K. (2009) Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci, 30: 25-31.
10. Corti, C., Crepaldi, L., Mion, S., Roth, A. L., Xuereb, J. H. and Ferraguti, F. (2007) Altered dimerization of metabotropic glutamate receptor 3 in schizophrenia. Biol Psychiatry, 62: 747-755. (Pubitemid 47374649)
11. Darrah, J. M., Stefani, M. R. and Moghaddam, B. (2008) Interaction of N-methyl-D-aspartate and group 5 metabotropic glutamate receptors on behavioral flexibility using a novel operant set-shift paradigm. Behav Pharmacol, 19: 225-234.
12. Dudkin, K. N., Kruchinin, V. K. and Chueva, I. V. (2001) Neurophysiological correlates of delayed visual differentiation tasks in monkeys: The effects of the site of intracortical blockade of NMDA receptors. Neurosci Behav Physiol, 31: 207-218.
13. Egan, M. F., Straub, R. E., Goldberg, T. E., Yakub, I., Callicott, J. H., Hariri, A. R., Mattay, V. S., Bertolino, A., Hyde, T. M., Shannon-Weickert, C., Akil, M., Crook, J., Vakkalanka, R. K., Balkissoon, R., Gibbs, R. A., Kleinman, J. E. and Weinberger, D. R. (2004) Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci USA, 101: 12604-12609.
14. Fell, M. J., Svensson, K. A., Johnson, B. G. and Schoepp, D. D. (2008) Evidence for the role of metabotropic glutamate (mGlu) 2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R, 4S, 5S, 6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther, 326: 209-217.
15. Flicker, A. C., Mok, M. H., de la Flor, R., Shah, A. J., Woolley, M., Dawson, L. A. and Kew, J. N. (2009) Effects of N-acetylaspartylglutamate (NAAG) at group II mGluRs and NMDAR. Neuropharmacology, 56: 1060-1067.
16. Galici, R., Echemendia, N. G., Rodriguez, A. L. and Conn, P. J. (2005) A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J Pharmacol Exp Ther, 315: 1181-1187.
17. Gewirtz, J. C. and Marek, G. J. (2000) Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacology, 23: 569-576.
18. Ghose, S., Crook, J. M., Bartus, C. L., Sherman, T. G., Herman, M. M., Hyde, T. M., Kleinman, J. E. and Akil, M. (2008) Metabotropic glutamate receptor 2 and 3 gene expression in the human prefrontal cortex and mesencephalon in schizophrenia. Int J Neurosci, 118: 1609-1627.
19. Ghose, S., Gleason, K. A., Potts, B. W., Lewis-Amezcua, K. and Tamminga, C. A. (2009) Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: A mechanism for antipsychotic drug action? Am J Psychiatry, 166: 812-820.
20. González-Maeso, J., Ang, R. L., Yuen, T., Chan, P., Weisstaub, N. V., López-Giménez, J. F., Zhou, M., Okawa, Y., Callado, L. F., Milligan, G., Gingrich, J. A., Filizola, M., Meana, J. J. and Sealfon, S. C. (2008) Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature, 452: 93-97.
21. Greenslade, R. G. and Mitchell, S. N. (2004) Selective action of (-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY379268), a group II metabotropic glutamate receptor agonist, on basal and phencyclidine-induced dopamine release in the nucleus accumbens shell. Neuropharmacology, 47: 1-8.
22. Harich, S., Gross, G. and Bespalov, A. (2007) Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment. Psychopharmacology (Berl), 192: 511-519. (Pubitemid 46870746)
23. Higgins, G. A., Ballard, T. M., Kew, J. N., Richards, J. G., Kemp, J. A., Adam, G., Woltering, T., Nakanishi, S. and Mutel, V. (2004) Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent. Neuropharmacology, 46: 907-917. (Pubitemid 38471944)
24. Imre, G., Fokkema, D. S. and Ter Horst, G. J. (2006) Subchronic administration of LY354740 does not modify ketamine-evoked behavior and neuronal activity in rats. Eur J Pharmacol, 544: 77-81. (Pubitemid 44164452)
25. Liu, F., Grauer, S., Kelley, C., Navarra, R., Graf, R., Zhang, G., Atkinson, P. J., Popiolek, M., Wantuch, C., Khawaja, X., Smith, D., Olsen, M., Kouranova, E., Lai, M., Pruthi, F., Pulicicchio, C., Day, M., Gilbert, A., Pausch, M. H., Brandon, N. J., Beyer, C. E., Comery, T. A., Logue, S., Rosenzweig-Lipson, S. and Marquis, K. L. (2008) ADX47273 [S-(4-fluoro-phenyl)- {3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: A novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J Pharmacol Exp Ther, 327: 827-839.
26. Marek, G. J., Wright, R. A., Schoepp, D. D., Monn, J. A. and Aghajanian, G. K. (2000) Physiological antagonism between 5-hydroxytryptamine (2A) and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther, 292: 76-87.
27. Moghaddam, B. and Adams, B. W. (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science, 281: 1349-1352.
28. Nakazato, A., Kumagai, T., Sakagami, K., Yoshikawa, R., Suzuki, Y., Chaki, S., Ito, H., Taguchi, T., Nakanishi, S. and Okuyama, S. (2000) Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1. 0]hexane-2,6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists. J Med Chem, 43: 4893-4909.
29. Neale, J. H., Bzdega, T. and Wroblewska, B. (2000) N- Acetylaspartylglutamate: The most abundant peptide neurotransmitter in the mammalian central nervous system. J Neurochem, 75: 443-452. (Pubitemid 30485424)
30. O'Brien, J. A., Lemaire, W., Wittmann, M., Jacobson, M. A., Ha, S. N., Wisnoski, D. D., Lindsley, C. W., Schaffhauser, H. J., Rowe, B., Sur, C., Duggan, M. E., Pettibone, D. J., Conn, P. J. and Williams, D. L. Jr. (2004) A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. J Pharmacol Exp Ther, 309: 568-577.
31. Ohnuma, T., Augood, S. J., Arai, H., McKenna, P. J. and Emson, P. C. (1998) Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Brain Res Mol Brain Res, 56: 207-217.
32. Olszewski, R. T., Bukhari, N., Zhou, J., Kozikowski, A. P., Wroblewski, J. T., Shamimi-Noori, S., Wroblewska, B., Bzdega, T., Vicini, S., Barton, F. B. and Neale, J. H. (2004) NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J Neurochem, 89: 876-885.
33. Olszewski, R. T., Wegorzewska, M. M., Monteiro, A. C., Krolikowski, K. A., Zhou, J., Kozikowski, A. P., Long, K., Mastropaolo, J., Deutsch, S. I. and Neale, J. H. (2008) Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors. Biol Psychiatry, 63: 86-91.
34. Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., Mosolov, S. N., Neznanov, N. G., Reznik, A. M., Smulevich, A. B., Tochilov, V. A., Johnson, B. G., Monn, J. A. and Schoepp, D. D. (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial. Nat Med, 13: 1102-1107.
35. Rorick-Kehn, L. M., Johnson, B. G., Knitowski, K. M., Salhoff, C. R., Witkin, J. M., Perry, K. W., Griffey, K. I., Tizzano, J. P., Monn, J. A., McKinzie, D. L. and Schoepp, D. D. (2007) In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology (Berl), 193: 121-136.
36. Sawaguchi, T. and Goldman-Rakic, P. S. (1994) The role of D1-dopamine receptor in working memory: Local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. J Neurophysiol, 71: 515-528.
37. 3H]LY354740, in rat brain. Mol Pharmacol, 53: 228-233.
38. 2/3 receptor agonist LY354740 in tests for antipsychotic-like activity. Eur J Pharmacol, 623: 73-83.
39. Shimazaki, T., Kaku, A. and Chaki, S. (2007) Blockade of the metabotropic glutamate 2/3 receptors enhances social memory via the AMPA receptor in rats. Eur J Pharmacol, 575: 94-97.